Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries

13 May 2025

Abstract excerpt

Group B Streptococcus (GBS) is a leading cause of infant mortality, particularly in low- and middle-income countries (LMICs). Several maternal GBS vaccine candidates, aimed at protecting infants, are progressing through clinical trials. The World Health Organisation (WHO) aims to ensure equitable access to safe, effective, and affordable vaccines of assured quality in LMICs, by facilitating regulatory pathways....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumonia and Respiratory Infections
Share to Vaccine Coverage and Hesitancy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40367817
DOI: 10.1016/j.vaccine.2025.127131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countriesPMID 40367817Read ↗

Serological thresholds of risk reduction for infant group B streptococcus diseaseSemantic proximity Read ↗

Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectivenessSemantic proximity Read ↗

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult womenSemantic proximity Read ↗

Potential for Maternally Administered Vaccine for Infant Group B StreptococcusSemantic proximity Read ↗

Progress toward a group B streptococcal vaccineSemantic proximity Read ↗

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trialSemantic proximity Read ↗

Acceptability and feasibility of maternal screening for Group B Streptococcus: a rapid reviewSemantic proximity Read ↗

Consultation report – considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countriesSemantic proximity Read ↗

Developing an Aggregator Mechanism for Late-Stage Clinical Trials of Neglected Disease Product CandidatesSemantic proximity Read ↗

COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant womenSemantic proximity Read ↗

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read ↗

Using Dried Blood Spots for a Sero-Surveillance Study of Maternally Derived Antibody against Group B StreptococcusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.